Menu

Peanut Allergy Treatment Works Long Term

Four years after taking a probiotic and peanut protein for 18 months, two-thirds of children in a small clinical trial can eat peanuts with no health issues.

Aug 17, 2017
Jef Akst

FLICKR, AIRPIXIn 2013, researchers at Murdoch Children’s Research Institute in Australia dosed 48 children either with a probiotic with increasing amounts of a peanut protein, a treatment known as PPOIT, or with a placebo once daily for a year and a half. This week (August 15), they reported that some 70 percent of the participants who received PPOIT can ingest peanut-containing foods with no adverse reactions, according to a study published in The Lancet Child & Adolescent Health.

That result represents only a slight dip from the original results that found 82 percent of the treated children could tolerate peanuts one month after finishing their PPOIT courses, suggesting the treatment is the first long-lasting option for those who suffer from a peanut allergy.

“These children had been eating peanut freely in their diet without having to follow any particular program of peanut intake in the years after treatment was completed,” lead researcher Mimi Tang says in a statement sent to The Scientist. “This is a major step forward in identifying an effective treatment to address the food allergy problem in Western societies.”

The probiotic used was Lactobacillus rhamnosus, a bacterium that may help mitigate allergic symptoms. “The probiotic acts on the immune system, encourages the immune system to generate a protective, or tolerance, response rather than allergy,” says Tang, according to ABC. “When given regularly over time, we hope to see the immune system recognise the antigen.” The next step is to trial PPOIT in a larger study. 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.